Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Shanghai Junshi Biosciences

Tracked across 3 events · 22 articles · First seen May 21, 2026 · Last active Aug 27, 2026

Sentiment
77
Attention
4
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 75
Tech
Impact: The China — National Medical Products Administration (NMPA) approved the new drug application (NDA) for toripalimab in combination with disitamab vedotin for HER2-expressing urothelial carcinoma, marking the 13th approved indication for toripalimab in the Chinese Mainland. This approval is a significant milestone for Shanghai Junshi Biosciences>>> and deepens its impact across the immunotherapy landscape.
May 21, 2026 · 6 articles
4 75
Business
Impact: Shanghai Junshi Biosciences Co., Ltd has entered into a licensing agreement with Fosun International — Fosun Wanbang Pharma Group for roconkibart, receiving an upfront payment and potential milestone payments and royalties. This collaboration expands its autoimmune disease treatment portfolio and validates its innovative capabilities.
Jul 01, 2026 · 8 articles
2 80
Business
Impact: Core entity; reported strong H1 2026 results with 45% revenue growth and profitability, advanced pipeline, and secured licensing deals.
Aug 26, 2026 · 8 articles
ERGEN INTELLIGENCE
Track Shanghai Junshi Biosciences live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.